NCT00390078View on ClinicalTrials.gov

Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

January 31, 2009

Conditions

HIV Infections

Interventions

BIOLOGICAL

MVA-mBN32

3 immunizations: 1x 10E8\_TCID50 MVA-mBN32

BIOLOGICAL

IMVAMUNE

3 immunizations: 1x 10E8\_TCID50 IMVAMUNE

Trial Locations (1)

13353

Charité, Campus Virchow-Klinikum, Berlin

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

collaborator

National Institutes of Health (NIH)

NIH

lead

Bavarian Nordic

INDUSTRY